Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Short term Debt (2023 - 2024)

TScan Therapeutics (TCRX) has disclosed Short term Debt for 2 consecutive years, with $10.3 million as the latest value for Q2 2024.

  • Quarterly Short term Debt changed N/A to $10.3 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $10.3 million through Jun 2024, changed N/A year-over-year, with the annual reading at $3.3 million for FY2023, N/A changed from the prior year.
  • Short term Debt for Q2 2024 was $10.3 million at TScan Therapeutics, up from $6.8 million in the prior quarter.
  • The five-year high for Short term Debt was $10.3 million in Q2 2024, with the low at $1.1 million in Q3 2023.